ArticleJournal of controlled release : official journal of the Controlled Release Society2013
Turning an antiviral into an anticancer drug: nanoparticle delivery of acyclovir monophosphate.
Article in Journal of controlled release : official journal of the Controlled Release Society, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 44 citations in OpenAlex.
- Nanoparticles for antiviral nucleotide analogs: approaches and analytical challenges.Journal of virology · 2026Review
- A portable poison exon for small-molecule control of mammalian gene expression.Nature methods · 2025Article
- Recent Advances in the Synthesis of Acyclic Nucleosides and Their Therapeutic Applications.Topics in current chemistry (Cham) · 2024Review
- ACV with/without IVM: a new talk on intestinal CDX2 and muscular CD34 and Cyclin D1 duringHelminthologia · 2024Article
- Clinical efficacy of washed microbiota transplantation on metabolic syndrome and metabolic profile of donor outer membrane vesicles.Frontiers in nutrition · 2024Article
- Incorporation ofInternational journal of molecular sciences · 2023Article
- Critical Review of Synthesis, Toxicology and Detection of Acyclovir.Molecules (Basel, Switzerland) · 2021Review
- Two nanoformulations induce reactive oxygen species and immunogenetic cell death for synergistic chemo-immunotherapy eradicating colorectal cancer and hepatocellular carcinoma.Molecular cancer · 2021Article
- Fabrication and Characterization of Calcium-Phosphate Lipid System for Potential Dental Application.Frontiers in chemistry · 2020Article
- Selected nucleos(t)ide-based prescribed drugs and their multi-target activity.European journal of pharmacology · 2019Review
- Gemcitabine nanoparticles promote antitumor immunity against melanoma.Biomaterials · 2019Article
- Nanoformulations for combination or cascade anticancer therapy.Advanced drug delivery reviews · 2017Review
- Quercetin Remodels the Tumor Microenvironment To Improve the Permeation, Retention, and Antitumor Effects of Nanoparticles.ACS nano · 2017Article
- Current and Future Theranostic Applications of the Lipid-Calcium-Phosphate Nanoparticle Platform.Theranostics · 2016Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Anti-herpes simplex virus (HSV) drug acyclovir (ACV) is phosphorylated by the viral thymidine kinase (TK), but not the cellular TK. Phosphorylated ACV inhibits cellular DNA synthesis and kills the infected cells. We hypothesize that ACV monophosphate (ACVP), which is an activated metabolite of ACV, should be efficient in killing cells independent of HSV-TK. If so, ACVP should be a cytotoxic agent if properly delivered to the cancer cells. The Lipid/Calcium/Phosphate (LCP) nanoparticles (NPs) with a membrane/core structure were used to encapsulate ACVP to facilitate the targeted delivery of ACVP to the tumor. The LCP NPs showed entrapment efficiency of ~70%, the nano-scaled particle size and positive zeta potential. Moreover, ACVP-loaded LCP NPs (A-LCP NPs) exhibited concentration-dependent cytotoxicity against H460 cells and increased S-phase arrest. More importantly, a significant reduction of the tumor volume over 4 days following administration (p<0.05-0.005) of A-LCP NPs, suggests excellent in vivo efficacy. Whereas, two free drugs (ACV and ACVP) and blank LCP NPs showed little or no therapeutic effect. It was also found that the high efficacy of A-LCP NPs was associated with the ability to induce dramatic apoptosis of the tumor cells, as well as significantly inhibit tumor cell proliferation and cell cycle progression. In conclusion, with the help of LCP NPs, monophosphorylation modification of ACV can successfully modify an HSV-TK-dependent antiviral drug into an anti-tumor drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.